126 related articles for article (PubMed ID: 18786866)
1. Inter-institutional variation of implant activity for permanent prostate brachytherapy.
Aronowitz JN; Crook JM; Michalski JM; Sylvester JE; Merrick GS; Mawson C; Pratt D; Naidoo D; Butler WM; Karolczuk K
Brachytherapy; 2008; 7(4):297-300. PubMed ID: 18786866
[TBL] [Abstract][Full Text] [Related]
2. Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis.
Merrick GS; Butler WM; Wallner KE; Blasko JC; Michalski J; Aronowitz J; Grimm P; Moran BJ; McLaughlin PW; Usher J; Lief JH; Allen ZA
Brachytherapy; 2005; 4(4):241-51. PubMed ID: 16344253
[TBL] [Abstract][Full Text] [Related]
3. Optimal equations for describing the relationship between prostate volume, number of sources, and total activity in permanent prostate brachytherapy.
Aronowitz JN; Michalski JM; Merrick GS; Sylvester JE; Crook JM; Butler WM; Mawson C; Pratt D; Naidoo D; Karolczuk K
Am J Clin Oncol; 2010 Apr; 33(2):164-7. PubMed ID: 20010076
[TBL] [Abstract][Full Text] [Related]
4. Favorable toxicity and biochemical control using real-time inverse optimization technique for prostate brachytherapy.
Raben A; Rusthoven KE; Sarkar A; Glick A; Benge B; Jacobs D; Raben D
Brachytherapy; 2009; 8(3):297-303. PubMed ID: 19213608
[TBL] [Abstract][Full Text] [Related]
5. Is a loose-seed nomogram still valid for prostate brachytherapy in a stranded-seed era?
Kudchadker RJ; Swanson DA; Kuban DA; Lee AK; Bruno TL; Frank SJ
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):623-7. PubMed ID: 18410998
[TBL] [Abstract][Full Text] [Related]
6. Dosimetry accuracy as a function of seed localization uncertainty in permanent prostate brachytherapy: increased seed number correlates with less variability in prostate dosimetry.
Su Y; Davis BJ; Furutani KM; Herman MG; Robb RA
Phys Med Biol; 2007 Jun; 52(11):3105-19. PubMed ID: 17505092
[TBL] [Abstract][Full Text] [Related]
7. Dynamic dose-feedback prostate brachytherapy in patients with large prostates and/or planned transurethral surgery before implantation.
Acher PL; Popert R; Morris SL; Potters L; Austin-Smith SL; Johnson UH; Nichol JE; Beaney RP
BJU Int; 2007 May; 99(5):1066-71. PubMed ID: 17233801
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy.
Ali I; Algan O; Thompson S; Sindhwani P; Herman T; Cheng CY; Ahmad S
Phys Med Biol; 2009 Sep; 54(18):5595-611. PubMed ID: 19717887
[TBL] [Abstract][Full Text] [Related]
9. Update on brachytherapy in localized prostate cancer: the importance of dosimetry.
Urbanic JJ; Lee WR
Curr Opin Urol; 2006 May; 16(3):157-61. PubMed ID: 16679852
[TBL] [Abstract][Full Text] [Related]
10. An innovative dosimetric model for formulating a semi-analytical solution for the activity-volume relationship in prostate implants.
Lee PC; Parks EK; Moran BJ
Med Dosim; 2003; 28(4):243-53. PubMed ID: 14684189
[TBL] [Abstract][Full Text] [Related]
11. A study of a pretreatment method to predict the number of I-125 seeds required for prostate brachytherapy.
Al-Qaisieh B; Brearley E; St Clair S; Flynn A
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):304-7. PubMed ID: 16618585
[TBL] [Abstract][Full Text] [Related]
12. Quality of permanent prostate implants using automated delivery with seedSelectron versus manual insertion of RAPID Strands.
Van Gellekom MP; Moerland MA; Wijrdeman HK; Battermann JJ
Radiother Oncol; 2004 Oct; 73(1):49-56. PubMed ID: 15465145
[TBL] [Abstract][Full Text] [Related]
13. Recommendations for permanent prostate brachytherapy with (131)Cs: a consensus report from the Cesium Advisory Group.
Bice WS; Prestidge BR; Kurtzman SM; Beriwal S; Moran BJ; Patel RR; Rivard MJ;
Brachytherapy; 2008; 7(4):290-6. PubMed ID: 18782682
[TBL] [Abstract][Full Text] [Related]
14. A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019.
Lee WR; Bae K; Lawton CA; Gillin MT; Morton G; Firat S; Baikadi M; Kuettel M; Greven K; Sandler H
Brachytherapy; 2006; 5(4):239-43. PubMed ID: 17118317
[TBL] [Abstract][Full Text] [Related]
15. Is an 192Ir permanent seed implant feasible for prostate brachytherapy?
Glasgow GP; Dogan N; Mohideen N
Brachytherapy; 2002; 1(4):195-203. PubMed ID: 15062167
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric guidance on using brachytherapy (low-dose-rate or high-dose-rate) to offset a flawed permanent prostate implant.
Zaider M
Brachytherapy; 2009; 8(1):40-4. PubMed ID: 19058764
[TBL] [Abstract][Full Text] [Related]
17. Novel prostate brachytherapy technique: improved dosimetric and clinical outcome.
Nobes JP; Khaksar SJ; Hawkins MA; Cunningham MJ; Langley SE; Laing RW
Radiother Oncol; 2008 Jul; 88(1):121-6. PubMed ID: 18499289
[TBL] [Abstract][Full Text] [Related]
18. Dosimetric outcomes in prostate brachytherapy: is downsizing the prostate with androgen deprivation necessary?
Gibbons EP; Jacobs BL; Smith RP; Beriwal S; Krishna K; Benoit RM
Brachytherapy; 2009; 8(3):304-8. PubMed ID: 19217354
[TBL] [Abstract][Full Text] [Related]
19. Intraoperative adaptive brachytherapy of iodine-125 prostate implants guided by C-arm cone-beam computed tomography-based dosimetry.
Westendorp H; Hoekstra CJ; van't Riet A; Minken AW; Immerzeel JJ
Brachytherapy; 2007; 6(4):231-7. PubMed ID: 17991620
[TBL] [Abstract][Full Text] [Related]
20. [Permanent implant prostate cancer brachytherapy].
Cosset JM; Flam T; Thiounn N; Pontvert D; Pierrat N; Vallancien G; Chauveinc L
Cancer Radiother; 2008 Nov; 12(6-7):503-11. PubMed ID: 18829365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
